Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Medical Device

Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism

Fineline Cube Aug 12, 2026

Shanghai Haohai Biological Technology Co. Ltd. (SHA: 688366) announced that its trifocal toric intraocular lens...

Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Fineline Cube Aug 12, 2026

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its self‑developed 9‑valent human...

Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that it has entered into...

Company Deals PIC

MSD Signs Oncology Collaboration With InventisBio Through MCICC to Accelerate Small‑Molecule Clinical Development

Fineline Cube Aug 12, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that it has signed a collaboration agreement...

Company Deals PIC

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Guangzhou Baiyunshan Xihe Health Medicine Co., Ltd. announced the...

Company Deals PIC

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Fineline Cube Aug 12, 2026

IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name:...

Company Deals

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

Fineline Cube Aug 12, 2026

Essex Bio-Technology (HKG: 1061) announced a strategic collaboration framework agreement with Gunze Medical Limited to...

Company Deals PIC

CanSino Biologics Reaches Cooperation Intent With Pakistan’s AGP Limited on PCV13i Pneumococcal Vaccine

Fineline Cube Aug 12, 2026

CanSino Biologics (HKG: 6185) announced that it reached a cooperation intent with its Pakistani partner...

Company Deals

Tempest Therapeutics Signs Strategic Partnership With Senlang to Advance TPST‑4003 In Vivo CAR‑T Candidate in China

Fineline Cube Aug 12, 2026

Tempest Therapeutics, Inc. (NASDAQ: TPST) announced a strategic partnership with Hebei Senlang Biotechnology Co., Ltd....

Company Deals

Zhaoke Ophthalmology Signs Strategic MOU With Brazil’s Teuto at BIO 2026 – First Latin America Eye‑Care Market Entry

Fineline Cube Aug 12, 2026

Zhaoke Ophthalmology Limited (HKG: 6622) announced that it signed a strategic cooperation memorandum with Brazilian...

Company Deals PIC

GRIT Biotechnology and Drug Farm Sign Deep Collaboration Agreement to Co‑Create KunEvo, an AI‑Native Biotech R&D Platform for First‑in‑Class Drug Discovery

Fineline Cube Aug 11, 2026

GRIT Biotechnology and Sino-US biotech company Drug Farm jointly announced a deep agreement to collaborate...

Company Deals PIC

Hangzhou Eli Radiopharma and Shanghai Smartlogic Sign Strategic Cooperation Agreement to Advance Computation‑Driven Radiopharmaceutical Discovery and Co‑Build Cyclic Peptide Platform

Fineline Cube Aug 11, 2026

Hangzhou Eli Radiopharma Co., Ltd. and Shanghai Smartlogic Technology Ltd. officially signed a strategic cooperation...

Company Deals

Sun-Novo and GemPharmatech Sign Long‑Term Strategic Cooperation Agreement to Deepen Preclinical Collaboration on Small Nucleic Acid Therapeutics and Build Closed‑Loop AOC R&D System

Fineline Cube Aug 11, 2026

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) and GemPharmatech Inc. (SHA: 688046) officially signed...

Company Deals

Gan & Lee Pharmaceuticals Signs Out‑Licensing Deal With Menarini on Bonfaglutide, a Twice‑Monthly GLP‑1 RA, Worth Up to EUR 726 Million Across 39 European Markets

Fineline Cube Aug 11, 2026

Gan & Lee Pharmaceuticals (SHA: 603087) announced an out‑licensing agreement with Menarini for Bonfaglutide Injection...

Company Drug

Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector

Fineline Cube Aug 11, 2026

Zhifei Biological (SHE: 300122) announced that it has submitted a clinical trial application in China...

Company Drug

Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps

Fineline Cube Aug 11, 2026

Keymed Biosciences Inc. (HKG: 2162) announced that the Phase 2 trial of CM512 injection, a...

Company Deals

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to USD 1.32 Billion, Gaining First‑in‑Class KCNT1 Ion Channel Inhibitor ABS‑1230 for Ultra‑Rare Epilepsy

Fineline Cube Aug 11, 2026

Jazz Pharmaceuticals (NASDAQ: JAZZ) announced that it will acquire Actio Biosciences, a privately held biopharmaceutical...

Company Drug

CSPC Pharmaceutical Group’s Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US

Fineline Cube Aug 11, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its Category 1 preventive biologic product SYS6037...

Company Deals

Novo Nordisk Names AWS Preferred Cloud Provider and Strategic AI Partner to Accelerate Drug Discovery With Agentic AI

Fineline Cube Aug 11, 2026

Novo Nordisk (NYSE: NVO) and Amazon Web Services (AWS) announced a strategic partnership to accelerate...

Company Deals

Xbiome and BioMap Sign Strategic Cooperation Agreement to Advance AI‑Powered Microbiome Drug and Probiotic Product R&D

Fineline Cube Aug 11, 2026

Xbiome, a China‑based AI‑driven microbiome drug development company, and BioMap officially signed a strategic cooperation...

Posts pagination

1 … 11 12 13 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.